We are live on ! Find out more

AMAG

AMAG Pharmaceuticals

AMAG

Delisted

AMAG was delisted on the 13th of November, 2020.

100 hedge funds and large institutions have $520M invested in AMAG Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New

Increased

Maintained

Reduced

Closed

9% more capital invested

Capital invested by funds: $477M → $520M (+$42.4M)

2% more call options, than puts

Call options by funds: $3.63M | Put options by funds: $3.55M

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

2% less funds holding

Funds holding: 102 → 100 (-2)

22% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 37

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders

100

Holders Change

-2

Holders Change %

-1.96%

% of All Funds

2.87%

Holding in Top 10

Holding in Top 10 Change

-1

Holding in Top 10 Change %

-50%

% of All Funds

0.03%

New

Increased

Reduced

Closed

Calls

$3.63M

Puts

$3.55M

Net Calls

+$81K

Net Calls Change

-$4.26M

Top Buyers

Rank	Fund	Capital Flow
1	BC Broadfin Capital New York	+$20.2M
2	DM Deerfield Management New York	+$8.58M
3	Bank of Montreal Toronto, Ontario, Canada	+$5.37M
4	State of New Jersey Common Pension Fund D Trenton, New Jersey	+$3.9M
5	Norges Bank Oslo, Norway	+$3.46M

Top Sellers

Rank	Fund	Capital Flow
1	T. Rowe Price Associates Baltimore, Maryland	-$18.4M
2	JGC J. Goldman & Co New York	-$8.79M
3	State Street Boston, Massachusetts	-$2.77M
4	Goldman Sachs New York	-$2.56M
5	Millennium Management New York	-$2.1M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	BCM 26 BBT Capital Management Fort Worth, Texas	$3.11M	+$2.77M	+150,000	New
27	MACM 27 March Altus Capital Management Greenwich, Connecticut	$3.03M	+$2.71M	+146,418	New
28	TI 28 Turner Investments Berwyn, Pennsylvania	$3M	+$2.68M	+144,810	New
29	JGC 29 J. Goldman & Co New York	$2.9M	-$8.79M	-475,500	-77%
30	30 Charles Schwab San Francisco, California	$2.86M	-$7.39K	-400	-0.3%
31	PI 31 Putnam Investments Boston, Massachusetts	$2.71M	+$2.42M	+130,839	New
32	32 Renaissance Technologies New York	$2.67M	+$72.1K	+3,900	+3%
33	QBFM 33 QS Batterymarch Financial Management New York	$2.61M	-$158K	-8,534	-6%
34	34 Geode Capital Management Boston, Massachusetts	$2.58M	+$77K	+4,165	+3%
35	35 Barclays London, United Kingdom	$2.42M	+$701K	+37,928	+46%
36	36 Bank of New York Mellon New York	$2.4M	-$66.4K	-3,594	-3%
37	GTC 37 Ghost Tree Capital New York	$2.07M	-$1.7M	-92,057	-48%
38	AIS 38 AlphaOne Investment Services West Chester, Pennsylvania	$2.02M	+$1.8M	+97,448	New
39	RCAMU 39 Rothschild & Co Asset Management US Stamford, Connecticut	$2M	–	–	–
40	40 Deutsche Bank Frankfurt Am Main Ge, Germany	$1.93M	-$187K	-10,128	-10%
41	TCIM 41 TIAA CREF Investment Management New York	$1.8M	-$681K	-36,857	-30%
42	42 California Public Employees Retirement System Sacramento, California	$1.64M	–	–	–
43	GC 43 Guggenheim Capital Chicago, Illinois	$1.47M	+$1.31M	+70,931	New
44	BIM 44 BlackRock Investment Management Wilmington, Delaware	$1.38M	+$125K	+6,738	+11%
45	45 Two Sigma Investments New York	$1.31M	-$250K	-13,548	-18%
46	46 Goldman Sachs New York	$1.25M	-$2.56M	-138,650	-70%
47	TCM 47 Tamarack Capital Management Carlsbad, California	$1.22M	+$1.18M	+64,080	New
48	CA 48 Continental Advisors Park City, Utah	$1.19M	+$1.06M	+57,438	New
49	AC 49 Amici Capital New York	$1.04M	+$924K	+50,000	New
50	NSEDCP 50 NJ State Employees Deferred Compensation Plan Trenton, New Jersey	$828K	–	–	–

AMAG Hedge Fund Activity: Q2 2014 in Review

100 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2014, worth a combined $520M — up 8.9% from $477M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of AMAG and 18 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 29 added.

The largest buyer was Broadfin Capital, adding an estimated $20.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $18.4M.

100 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2014, down from 102 in Q1 2014.
Funds reported $520M of AMAG Pharmaceuticals stock for Q2 2014, up 8.9% quarter-over-quarter.
18 funds opened new AMAG Pharmaceuticals positions in Q2 2014 and 19 closed out, a net change of -1 holder.
The largest AMAG Pharmaceuticals buyer in Q2 2014 was Broadfin Capital, an estimated $20.2M added.
The largest AMAG Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $18.4M sold.

Based on aggregated 13F filings for Q2 2014.

AMAG Pharmaceuticals AMAG